GlycoMimetics Inc (GLYC)
0.3169
0.00 (0.00%)
USD |
NASDAQ |
Nov 22, 15:28
GlycoMimetics Total Assets (Quarterly): 15.70M for Sept. 30, 2024
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 15.70M |
| June 30, 2024 | 24.42M |
| March 31, 2024 | 34.20M |
| December 31, 2023 | 45.32M |
| September 30, 2023 | 53.20M |
| June 30, 2023 | 61.82M |
| March 31, 2023 | 68.92M |
| December 31, 2022 | 51.81M |
| September 30, 2022 | 55.96M |
| June 30, 2022 | 65.04M |
| March 31, 2022 | 81.46M |
| December 31, 2021 | 94.35M |
| September 30, 2021 | 107.94M |
| June 30, 2021 | 124.38M |
| March 31, 2021 | 138.02M |
| December 31, 2020 | 142.83M |
| September 30, 2020 | 150.42M |
| June 30, 2020 | 158.35M |
| March 31, 2020 | 162.10M |
| December 31, 2019 | 167.97M |
| September 30, 2019 | 180.45M |
| June 30, 2019 | 192.33M |
| March 31, 2019 | 204.44M |
| December 31, 2018 | 214.84M |
| Date | Value |
|---|---|
| September 30, 2018 | 225.17M |
| June 30, 2018 | 235.70M |
| March 31, 2018 | 247.42M |
| December 31, 2017 | 128.58M |
| September 30, 2017 | 115.82M |
| June 30, 2017 | 121.62M |
| March 31, 2017 | 37.17M |
| December 31, 2016 | 42.39M |
| September 30, 2016 | 48.01M |
| June 30, 2016 | 55.77M |
| March 31, 2016 | 40.70M |
| December 31, 2015 | 48.46M |
| September 30, 2015 | 55.74M |
| June 30, 2015 | 62.04M |
| March 31, 2015 | 48.46M |
| December 31, 2014 | 57.26M |
| September 30, 2014 | 62.43M |
| June 30, 2014 | 67.52M |
| March 31, 2014 | 58.06M |
| December 31, 2013 | 5.284M |
| September 30, 2013 | 9.561M |
| June 30, 2013 | 11.55M |
| December 31, 2012 | 18.42M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
15.70M
Minimum
Sep 2024
167.97M
Maximum
Dec 2019
90.21M
Average
75.19M
Median
Total Assets (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 6.851B |
| Arbutus Biopharma Corp | 140.44M |
| Revance Therapeutics Inc | 461.56M |
| FibroGen Inc | 264.42M |
| Cidara Therapeutics Inc | 162.33M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 4.322M |
| Shareholders Equity (Quarterly) | 11.38M |